LPM3770164 sustained release tablet ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
8Huntington disease1

8. Huntington disease


Clinical trials : 229 Drugs : 193 - (DrugBank : 60) / Drug target genes : 84 - Drug target pathways : 158
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05238701
(ClinicalTrials.gov)
February 28, 20229/1/2022A Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 in Healthy SubjectsA Randomized, Double-blinded, Placebo-controlled, Dose-escalation Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 Sustained-release Tablets in Healthy SubjectsHuntington Disease;Tardive DyskinesiaDrug: LPM3770164 sustained release tablet;Drug: LPM3770164 sustained release tablet simulantLuye Pharma Group Ltd.NULLNot yet recruiting18 Years45 YearsAll104Phase 1China